Meeting
2015 ASCO Annual Meeting
Comparison of concurrent use of carboplatin-Paclitaxel versus cisplatin-etoposide with thoracic radiation for stage III NSCLC patients: A systematic review.
Authors
Conor Ernst Steuer
Emory Univ, Atlanta, GA
Conor Ernst Steuer , Madhusmita Behera , Kristin Ann Higgins , Nabil F. Saba , Dong Moon Shin , Suchita Pakkala , Rathi Narayana Pillai , Taofeek Kunle Owonikoko , Walter John Curran Jr., Chandra Prakash Belani , Fadlo Raja Khuri , Suresh S. Ramalingam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 7536)
DOI
10.1200/jco.2015.33.15_suppl.7536
Abstract #
7536
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2011 ASCO Annual Meeting
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy (TTR) followed by gemcitabine and carboplatin consolidation in patients with unresectable stage III non-small cell lung cancer (NSCLC): NCT 00449657.
First Author: J. Zhang
Poster
2018 ASCO Annual Meeting
Long-term results of a phase I/II trial of nelfinavir with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
First Author: Ramesh Rengan
Poster
2017 ASCO Annual Meeting
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018).
First Author: Kaoru Kubota